報價延遲最少15分鐘:2026/04/21 21:21 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-11.73/-0.54
|
|
企業價值
5.00M
|
| 資產負債 |
|
每股賬面淨值
-2.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.01M
|
|
每股收益
0.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| 60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees. |
